DCL treatment alleviated the progression of DSS-induced colitis through its anti-inflammatory effects by suppressing the NF-κB and MAPK pathways as well as by activating the Nrf2 signalling cascade (Figure 10). This evidence concerns the gene NFE2L2 and colitis.